API Form and Solid-State Research
Solid Form Screening and Selection
en
-横版-原色.webp "Crystal Pharmatech Co., Ltd."){kind=logo}
Solid form screening integrates polymorph screening, salt screening, and co-crystal screening to establish a complete understanding of solid-state diversity. Screening conditions are systematically designed based on solubility, molecular structure, and intermolecular interactions to ensure broad and efficient coverage of potential solid forms.
Extensive application across more than 1,500 drug molecules has demonstrated the effectiveness of these screening strategies in identifying optimal solid forms for development.
Early-stage screening focuses on rapidly identifying thermodynamically stable crystal forms using targeted experimental design. Structural analysis and physicochemical profiling enable prediction of salt and co-crystal formation potential, allowing efficient screening with reduced material consumption and accelerated timelines.
For compounds entering clinical development, screening strategies expand to ensure comprehensive identification of all relevant solid forms, including metastable forms. This supports intellectual property protection and ensures robustness for industrial development through systematic and tiered screening approaches.
Subscribe to be the first to get the updates!
